IFNA1 and autoimmune disease: Although a growing number of studies have investigated Siglec-1 as an ex vivo biomarker in IFN-driven autoimmune diseases, our current study demonstrates its utility as an accurate in vitro read-out for type I IFN-mediated responses [11, 14–18, 27].